Strategic Partnerships Surfacide has a history of strategic collaborations with large healthcare systems and distributors (MedStar Health, PathTrac, Fidelis Sustainability Distribution) and engages with government channels. Sales opportunities exist in expanding partner networks, leveraging these channels to reach more hospitals, long-term care facilities, and public venues.

Expansion of UV-C Adoption With the Helios+ system being FDA-authorized for whole-room microbial reduction and a track record in 600+ deployments, there is potential to upsell to institutions seeking comprehensive infection prevention upgrades, as well as to facilities expanding to ORs, pharmacies, and high-traffic areas with UV-C programs (SURFrx, Eos) to broaden use cases.

Government & Defense Channels Existing ECAT contract access and government-focused distribution partnerships indicate a pathway to secure multi-year, large-scale orders. Target opportunities include hospital networks, VA facilities, and public health institutions seeking compliant, hospital-grade disinfection solutions.

Integrated Disinfection Suite A portfolio that includes portable devices (Eos), program offerings (SURFrx), and PX initiatives suggests cross-sell opportunities within facilities that require both room-level and portable disinfection capabilities, enabling bundled procurement for comprehensive infection control programs.

Industry Growth & Validation A proven deployment footprint in diverse settings and ongoing press coverage around partnerships and product launches signals momentum. Sales teams can leverage case studies and FDA-cleared efficacy to persuade hospital procurement, infection prevention teams, and facilities management about ROI and risk reduction.